Spyre Therapeutics (SYRE) to Release Earnings on Wednesday

Key Points

• Spyre Therapeutics is set to release its Q2 2025 earnings on August 6th, with analysts anticipating an earnings per share loss of ($0.68).
• Institutional investor MIRAE ASSET GLOBAL ETFS HOLDINGS increased its holdings in Spyre Therapeutics by 18.8%, reflecting growing interest in the stock.
• Five research analysts currently rate Spyre Therapeutics with a "buy" recommendation, indicating positive market sentiment, while the stock has a consensus price target of $53.40.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Spyre Therapeutics Trading Down 4.2%

Shares of SYRE stock traded down $0.71 on Friday, reaching $16.26. The company's stock had a trading volume of 551,674 shares, compared to its average volume of 540,586. The stock's fifty day simple moving average is $16.19 and its 200-day simple moving average is $17.10. Spyre Therapeutics has a 1 year low of $10.91 and a 1 year high of $40.26. The company has a market capitalization of $980.15 million, a price-to-earnings ratio of -4.31 and a beta of 2.82.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SYRE shares. Wedbush restated an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, May 5th. Leerink Partnrs upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Finally, Leerink Partners started coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $53.40.

Institutional Trading of Spyre Therapeutics

An institutional investor recently raised its position in Spyre Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 18.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,018 shares of the company's stock after purchasing an additional 4,277 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Spyre Therapeutics were worth $442,000 at the end of the most recent quarter. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).